Quoin obtains EU orphan drug designation.
Quoin Pharmaceutical’s QRX003 has been granted Orphan Drug Designation in Europe for the treatment of Peeling Skin Syndrome, providing market exclusivity and supporting the initiation of a clinical trial before year end.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed